Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

This innovative FTSE 250 stock has had a solid start to the year, rising 15% in just two days. Is it time I considered adding ...

What stocks offer the most profit potential in the new year? Three contributors go into more detail about their six picks for ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

This stock can be held in an Investment ISA and an Investment Account ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country ...